Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer ...

Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.

Novo Nordisk boasts 45 million customers using their drug Ozempic, which has caused a revolution in weight-loss treatment.

Novo Nordisk is also developing an oral drug for obesity, amycretin, which also performed better than Wegovy in a phase 3 obesity trial and is in mid-stage development. New approval for Zepbound ...

Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...

New York, New York-- (Newsfile Corp. - February 9, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Saxenda continues to develop a dominant position in obesity pharmacotherapy however, and Novo Nordisk said the drug currently has a market share of 63% worldwide. The company’s GLP-1 agonists ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

The decliners were Novo Nordisk (NYSE: NVO), famously the company behind Wegovy, and Viking Therapeutics (NASDAQ: VKTX), which is far along in its development of an advanced GLP-1-based obesity ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...